The Sleeping Bruxism Treatment Market size is projected to be worth USD 1.03 Billion by 2032, registering a CAGR of 6% during the forecast period.

Sleep bruxism, characterized by the involuntary grinding or clenching of teeth during sleep, is a prevalent dental condition affecting a significant portion of the global population. The demand for effective night bruxism treatment has fueled the growth of the Sleeping Bruxism Treatment market, addressing the need for solutions to alleviate the associated discomfort and prevent dental complications.

The market for night bruxism treatment encompasses a wide range of products and therapies designed to mitigate the impact of sleep bruxism. Dental professionals and researchers have been actively engaged in developing innovative solutions, contributing to the expansion of treatment options. Custom-fitted night guards, one of the primary interventions, are designed to provide a protective barrier between the upper and lower teeth, minimizing the damage caused by grinding.

Additionally, behavioral therapies and relaxation techniques have gained prominence in the sleep bruxism treatment landscape. Stress and anxiety, often linked to the condition, can be addressed through cognitive-behavioral approaches, offering a holistic treatment perspective. As awareness regarding the long-term consequences of untreated sleep bruxism grows, individuals are increasingly seeking professional guidance for tailored treatment plans.

The market is witnessing a surge in research and development activities aimed at introducing advanced diagnostics and treatment modalities. Technological advancements, such as wearable devices and smart oral appliances, are being explored to provide real-time monitoring and feedback, enhancing the overall effectiveness of sleep bruxism management.

Major Key Players:

The Sleeping Bruxism Treatment Companies are Pfizer Inc. (U.S.), Ipsen Biopharmaceuticals, Inc. (U.S.), Henry Schein, Inc. (U.S.), Carestream Dental (U.S.), PLANMECA OY (Finland), Akervall Technologies Inc. (U.S.), Merz Pharma GmbH & Co. KGaA (Germany), Randmark Dental Products, LLC (U.S.), S4S Dental Laboratory (U.K.), Patterson Dental Supply, Inc. (U.S.), Ivoclar Vivadent AG (Liechtenstein), and others.

Segment Analysis

MRFR’s market study with regard to sleeping bruxism treatment covers segments like type, diagnosis, treatment type, cause, patient type, and end-user.

The main types considered in the market report include primary as well as secondary. The largest market in 2017 belonged to secondary bruxism, as a result of the surge in sleep disorders, rising intake of medicines that cause dental issues and evolving lifestyles in light of growing stress.

Treatment-wise, the key market categories can be dental approaches as well as medication. The dental approaches-based segments in the market are NTI-tss device and mouth guard. The medication-wise categories include Botox injections, anti-anxiety drugs and muscle relaxants.

The key causes of sleeping bruxism identified in the market study include sleep paralysis, obstructive sleep apnea, malocclusion, gastroesophageal reflux disease (GERD), and more. Between these, the obstructive sleep apnea category can touch USD 233.20 million by 2023, and also achieve an expansion rate of 7.0% during the given period.

Pediatric and adult remain the two patient type segments in the market. In the year 2017, the pediatric segment took the lead, as hyperactivity has become quite prevalent among children, in addition to anger issues, rising pain from teething and earache, and stress.

Some of the prominent end-users in the worldwide industry are dental clinics, hospitals, and others.

Recent Development

September 2023: Studio Z Dental currently provides personalized dental appliances for patients in the US because to recent studies demonstrating that these devices can be just as successful as CPAP machines in treating mild, moderate, and severe OSA. Sudden awakenings during the night, gasping for air, snoring, chronic headaches, depression, and daytime fatigue can all be symptoms of sleep apnea. In addition to treating sleep apnea, the clinic offers comprehensive treatment regimens for TMD and nighttime bruxism. Since untreated sleep apnea has been related to heart failure, cardiac arrest, hypertension, and other cardiovascular disorders, Studio Z Dental is urging anyone who suffer from it to make an appointment as soon as possible following the recent news.

May 2022: Daewoong Pharmaceutical Co. of South Korea is working hard to increase the reach of its botulinum toxin product Nabota beyond purely cosmetic uses. Nabota is a highly purified botulinum toxin product made using proprietary technology. It includes over 98% of the 900 kDa protein, which is the most stable and effective form of the toxin. Clinical trials including Nabota are now being conducted to confirm its efficacy in treating male-pattern hair loss, scarless thyroidectomy, therapy of epiphora, improvement of postherpetic neuralgia, sleep bruxism, hot flashes, and other conditions. In Korea, Nabota is used to treat upper limb muscular stiffness and eyelid spasm following stroke, as well as for cosmetic purposes such reducing the appearance of glabellar lines and wrinkles around the eyes.

Regional Analysis

The Americas, the Middle East and Africa/MEA, Asia Pacific/APAC and Europe are the top markets for sleeping bruxism treatment.

The Americas, in 2017, measured up to a share of 39.1% in the sleeping bruxism treatment market. The key growth promoters include the escalating anxiety and stress among people and the significant surge in government spending on the target field. Mounting healthcare insurance among people also contributes to the expansion of the regional market. A few other factors encouraging market growth can be the rising introduction of innovative and advanced devices, and the burgeoning geriatric population in the region, especially in the United States, Mexico and Canada. 

Europe has procured the second position in the global market, due to the apparent surge in sleeping bruxism cases among children and adults alike. Strong economy, expanding dental awareness and high number of dental clinics aid significantly in the market growth in Europe. An expanding pool of patients suffering from snoring, irregular breathing and sleep disorders has also given a boost to sleeping bruxism, marking substantial market progress in the region.

With a steady advancement rate, the APAC market is largely backed by the rapid increase in the use of quality healthcare technology, fast economic growth and the massive population. Increasing spending on healthcare and the considerable expansion of the pediatric population also serves as catalysts in the market growth here. The growing knowledge level among people about sleep bruxism and the thriving dental industry in India, Japan, South Korea and China also bolster the market demand in APAC.

Browse Related Reports:

Menopause Treatment Market

Sleeping Bruxism Treatment Market

Artificial Intelligence in Healthcare Market

Veterinary Pain Management Market

Bariatric Surgery Devices Market

For More Information, Please Visit @ Market Research Future